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SERUM AND FECAL BIOMARKERS PREDICT RESPONSE TO INFLIXIMAB 




 Inflammatory Bowel Disease (IBD) is a chronic, idiopathic autoimmune disease 
characterized by the inflammation of the GI tract. The main subcategories of IBD include 
Crohn Disease (CD), ulcerative colitis (UC), and Indeterminate Colitis (IC). Currently, 
IBD is diagnosed and evaluated using clinical, endoscopic, biochemical, and histologic 
measures - which can be invasive and costly. Previous studies have shown that 
measurement of serum and fecal inflammatory biomarkers might be effective both for the 
assessment of intestinal infectious or inflammatory processes, as well as for gauging IBD 
disease activity. Inflammatory biomarkers investigated in this study include serum and 
fecal Anti-Saccharomyces-Cerevisiae Antibody (ASCA), serum and fecal lactoferrin, 
fecal calprotectin, fecal hemoglobin, IL1-a, IL1-b, erythrocyte sedimentation rate (ESR), 
and C-reactive protein (CRP). IMPACT-III questionnaires are utilized to measure the 
quality of life in enrolled subjects. Data collected in this study investigated the 
relationship between changes in serum and fecal biomarker levels, clinical disease 
activity, and the mental wellbeing of patients. The primary objective was to measure 
changes in inflammatory biomarker levels in patients with CD, UC, and IC after being 
treated with the anti-TNF therapy Infliximab (Remicade). The second objective is to 
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study the relationship between changes in these biomarker levels and the clinical, 
biochemical, and endoscopic outcome parameters of IBD in patients.  
 This is a multicenter, longitudinal, cohort study following 50 pediatric patients 
with IBD over the course of six Remicade infusion appointments. The project was 
conducted in partnership with Riley’s Children Hospital in Indianapolis. Patients with  
CD, UC, and IC were recruited for the study and stratified with respect to the temporal 
phase of their Remicade infusions, including: 
• Induction 
• Past induction, but less than 6 months 
• Those who have been receiving Remicade for over one year.  
 A total of 58 eligible IBD patients are currently enrolled. 13 patients have 
withdrawn from the study, leaving 45 active patients: 27 CD, 17 UC, and 1 IC remaining 
in the prospective cohort. Patients provided serum and fecal samples and completed 
IMPACT-III questionnaires at the time of each Remicade infusion. Baseline serum 
ASCA levels were 0.014	±0.029 OD from (n=15) patients with CD, 0.0083	±0.022 OD in 
(n=12) patients with UC, and 0.002 OD in one patient with IC. Baseline fecal ASCA 
levels were 0.068	±0.186 OD in (n=10) patients with CD, 0.0018	±0.0013 OD in (n=9) 
patients with UC, and 0.001 OD  in one patient with IC. At both baseline and at the time 
of the first infusion, CRP levels were significantly higher in patients with CD (p<0.05). 
At the time of the first infusion, the ESR in patients with CD was significantly higher 
than that in patients with UC (p<0.10). Serum lactoferrin was significantly higher in 
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patients with UC at infusion 2 (p<0.05). ESR was significantly higher in patients with 
UC (p<0.10) at their fourth infusion.  
 Our data support the hypothesis that serum and fecal biomarkers are useful in 
evaluating the response of intestinal inflammation to Remicade therapy. This study is 
ongoing, and further sample collection and data analysis are needed to more conclusively 
determine the accuracy of inflammatory biomarkers as a diagnostic tool for use in the 








READER APPROVAL PAGE…………………………………………………………..iii 
ACKNOWLEDGMENTS .............................................................................................. iv	
ABSTRACT .................................................................................................................... v	
TABLE OF CONTENTS ............................................................................................ viii	
LIST OF TABLES .......................................................................................................... x	
LIST OF FIGURES ........................................................................................................ xi	
LIST OF ABBREVIATIONS ...................................................................................... xiii	
INTRODUCTION ........................................................................................................... 1	
Inflammatory Bowel Disease ................................................................................. 1	
Clinical Presentation of IBD .................................................................................. 7	
Diagnosis .............................................................................................................. 10	
Inflammatory Biomarkers of IBD ....................................................................... 12	
Treatments and Medications ............................................................................... 14	












LIST OF TABLES 
 
 
Table Title Page 
1 Signs and Symptoms of CD and UC 5 
2 Demographic Data 32 
3 Patient Population 33 
4 Baseline Data 36 





LIST OF FIGURES 
 
 
Figure Title Page 
1 Pathogenesis of Inflammatory Bowel Disease 2 
2 Colectomy Specimen  7 
3 UC versus CD Colon 9 
4 Demographic Data 22 
5 Paris Classification and Medications 23 
6 Disease Location 24 
7 Infusion Data  25 
8 Infusion Data (Continued) 26 
9 Infusion Data (Continued) 27 
10 Infusion Data (Continued) and IMPACT-III 28 
11 Enrollment and Special Testing 29 
12 Subsequent Colonoscopies 30 
13 Subsequent Colonoscopies (Continued) 31 
14 Recruited Patient Population 34 
15 Serum ASCA Levels by Infusion 38 
16 Fecal ASCA Levels by Infusion 38 
17 Serum Lactoferrin Levels by Infusion 40 
18 Fecal Lactoferrin Levels by Infusion 40 
	
	 xii 
19 Fecal Calprotectin Levels by Infusion 42 
20 Fecal Hemoglobin Levels by Infusion 43 
21 Fecal IL1-a	Levels	by	Infusion 44 
22 Fecal IL1-b	Levels	by	Infusion 45 
23 ESR by Infusion 46 
24 CRP by Infusion 47 





LIST OF ABBREVIATIONS 
 
ASCA............................................................... Anti-Saccharomyces Cerevisiae Antibody 
CBC .............................................................................................. Complete Blood Count 
CD .......................................................................................................... Crohn’s Disease 
CRP..................................................................................................... C-Reactive Protein 
ESR ................................................................................. Erythrocyte Sedimentation Rate 
FC ........................................................................................................ Fecal Calprotectin 
GI ............................................................................................................. Gastrointestinal 
HRQoL .............................................................................. Health Related Quality of Life 
IBD ...................................................................................... Inflammatory Bowel Disease 
IC ..................................................................................................... Indeterminate Colitis 
IL ..................................................................................................................... Interleukin 
Lf .................................................................................................................... Lactoferrin 
MRI..................................................................................... Magnetic Resonance Imaging 
QoC................................................................................................ Quality of Health Care 
Th-1 .................................................................................................T-Helper Cell Type 1 
Th-2 .................................................................................................T-Helper Cell Type 2 
TNF............................................................................................... Tumor Necrosis Factor 
UC .........................................................................................................Ulcerative Colitis 
WBC ...................................................................................................... White Blood Cell 





Inflammatory Bowel Disease 
 Inflammatory Bowel Disease (IBD), which encompasses both ulcerative colitis 
UC) and Crohn Disease (CD), is an autoimmune disease characterized by chronic 
inflammation occurring in the gastrointestinal (GI) tract. There is no single cause to 
explain the development of IBD. However, existing epidemiologic data support the roles 
played by both genetics and environmental exposures. These and other factors may 
contribute to an alteration of intestinal homeostasis by affecting the balance (defined 
along dimensions of both species and number) of a person’s fecal microbiota (Abraham 
& Cho, 2009). Net changes in the numbers and presence of particular bacteria may 
precipitate dysfunction of the intestinal immune system and a disturbance in mucosal 
epithelial barrier function (Grover 2019). 
 A single layer of tightly interconnected columnar epithelial cells serves as the 
physical barrier separating the contents of the intestinal lumen from the rest of the body. 
This epithelium is, in turn, supported by epithelial and sub-epithelial goblet and 
endocrine cells that both produce mucus (Fakhoury, Negrulj, Mooranian, & Al-Salami, 
2014) and secrete cytokines that promote epithelial restitution (Abraham & Cho, 2009). 
In patients with IBD, inflammation results in a breach in epithelial integrity that is 
characterized grossly as erosions, ulcerations (aphthae), and fissures. Any break in the 
epithelial lining exposes immunocompetent T cells in the mucosa and submucosa to 
pathogenic luminal contents, thereby precipitating a more intense dysregulated 
inflammatory response (Abraham & Cho, 2009). Over time, chronic inflammation causes 
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the epithelium to become increasingly distorted, as evidenced by local fibrosis and 
branching crypts (Fakhoury, Negrulj, Mooranian, & Al-Salami, 2014). 
 
 
Figure 1. Pathogenesis of Inflammatory Bowel Disease (Podolsky, 2002). 
 
The dysregulated intestinal inflammatory immune observed in patients with active 
IBD is likely initiated by a localized increase in the permeability of the GI epithelium, 
resulting from either a predetermined genetic underpinning or exposure to relevant 
infectious or noxious environmental stimuli. The influx of luminal contents into the 
subepithelial compartment activates resident immunocompetent B and T cells, which in 
turn release a programmed repertoire of inflammatory cytokines and chemokines 
(Abraham & Cho, 2009). One particular cytokine, Tumor Necrosis Factor (TNF), is 
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present in high concentration in the tissue of patients with IBD and plays a crucial role in 
orchestrating a localized and systemic inflammatory response in the body.  
Previous studies have proposed that a genetic mutation in the NOD2 protein, 
which is responsible for intracellular sensing of bacterial peptidoglycan (Abraham & 
Cho, 2009), is associated with the increased production of pro-inflammatory cytokines in 
individuals with IBD. Although genetic testing and twin/familial studies have elucidated 
the role played by NOD2 and other candidates, no single gene (or collection of genes) has 
proven diagnostically conclusive. Nonetheless, the years of observation and clinical 
research have identified additional (potentially modifiable) risk factors that are likely to 
contribute to the development of IBD including changes in diet, tobacco use, antibiotic 
use, and geographical location (Abraham & Cho, 2009). An example of this is the 
“hygiene hypothesis,” which proposes that characteristics of Western societies, including 
improved sanitation, lower rates of GI tract infectious diseases, smaller family size (urban 
areas), and increased antibiotic use, have resulted in a decreased exposure of the mucosal 
immune system to routine pathogens. Now relieved of its endemic challenges, the highly 
evolved immune system lining the gut has a lower threshold to respond to autoantigens 
and commensal bacteria. As such, there may be a plausible pathogenic link between how 
we live and the rising incidence of chronic autoimmune diseases that we are encountering 
today (Ponder & Long, 2013). 
The two main types of IBD presented in patients are Crohn’s Disease (CD) and 
Ulcerative Colitis (UC). Although CD and UC both belong in the overall IBD family, 
they are heterogenous diseases and differ in location, symptoms, and clinical 
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presentation. CD is characterized by a discontinuous, often transmural inflammation in 
the GI mucosa that can occur anywhere from the mouth to the anus but generally 
involves specifically the ileum and the colon (Papamichael et al., 2019). Intestinal 
strictures and fistulas are much more common in patients with CD, relative to those with 
UC, and the presence of non-necrotizing granulomas on biopsy is generally considered 
pathognomonic in the appropriate clinical context (Abraham & Cho, 2009). The 
histology of mucosal samples taken from patients with CD typically reveals large resident 
populations of CD4+ T cell lymphocytes with a helper T type 1 (Th-1) cell phenotype. 
In contrast, the mucosa of patients with UC has larger resident populations of CD4+ 
lymphocytes with a helper T type 2 (Th-2) cell phenotype (Podolsky, 2002).  
UC is characterized by a continuous, mucosal inflammation that is generally 
contained in the rectal region (Papamichael et al., 2019) and can involve a part or the 
whole colon, otherwise known as pancolitis (Abraham & Cho, 2009). The incidence of 
UC is about 1.2 to 20.3 cases per 100,000 persons a year (Danese & Fiocchi, 2011). The 
clinical and endoscopic picture of UC is more common in younger children (3-5 years), 
whereas the incidence of patients with CD symptoms appears to increase with age (13-17 












There is a subgroup of patients with IBD that are labelled as having 
“Indeterminate” disease, and these patients will manifest signs and symptoms consistent 
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with both UC and CD. Indeterminate Colitis (IC) occurs in approximately 10-15% of 
individuals with IBD who have not yet been diagnosed definitely with either CD or UC 
(Guindi & Riddell, 2004). It is common for pediatric patients to be diagnosed with IC 
because the initial clinical presentation and histology of the IBD may be challenging to 
distinguish between CD and UC. Although IC is considered a subgroup of IBD 
containing overlapping symptoms of CD and UC, it is not considered to be a definitive 
diagnosis of IBD (Guindi & Riddell, 2004). 
Currently, there are approximately 1.4 million Americans with IBD (Abraham & 
Cho, 2009) and around 25% of IBD patients are children or young adults (El-Matary, 
Dupuis, & Sokoro, 2015). Incidence and prevalence findings have been conflicting, and 
while up to 60% of studies report a rising incidence of CD relative to UC, up to 20% of 
studies measured an overall rise in the number of patients diagnosed with UC (Ponder & 
Long, 2013). Autoimmune diseases, in general, are becoming more prevalent in 
industrialized nations than in developing countries (Fakhoury, Negrulj, Mooranian, & Al-
Salami, 2014). Nonetheless, the incidence of IBD continues to grow in developing 
regions including Asia, Africa, and South America. In addition to environmental factors, 
excessive consumption of milk, animal proteins, polyunsaturated fatty acids, and tobacco 
also appear to increase the risk of developing IBD (Fao, Fan, Lv, Ji, & Xu, 2018) 
independently. On the other hand, adequate consumption of breast milk and proper 
nutrition can help reduce the chance of developing IBD and/or acquiring GI infections 




Clinical Presentation of IBD 
IBD is a local GI disease with systemic implications. Both adult and pediatric 
patients with IBD alternate between periods of clinical relapse and remission (Fao, Fan, 
Lv, Ji, & Xu, 2018). Although the initial clinical presentation of IBD can be similar in 
children and adults, the progression of pediatric-onset IBD is usually more severe than 




Figure 2. Colectomy specimen from a patient with refractory IBD. Longitudinal 
ulcers, barely intact mucosa (Guindi & Riddell, 2004). 
 
 Patients with either UC or CD generally present with diarrhea, abdominal pain, 
fatigue, and growth disorders (Seyedian, Nokhostin, & Malamir, 2019). As stated 
previously, CD and UC are heterogenous forms of IBD and can be further differentiated 
through the unique clinical hallmarks of each disease. Patients with UC typically present 
with pain in the left lower quadrant and the hypogastrium. Bloody diarrhea usually 
develops shortly after that (Danese & Fiocchi, 2011). Other clinical stigmata of UC 
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include weight loss, a radiographic demonstration of colonic dilation (Baumgart & 
Sandborn, 2007), an increase in the frequency of bowel movements, and the presence of 
blood in the stool (Fakhoury, Negrulj, Mooranian, & Al-Salami, 2014; Baumgart & 
Sandborn, 2007). The mucosa of patients with active UC is characterized by ulcerations, 
friability, and an absent mucosal vascular pattern (Danese & Fiocchi, 2011). UC disease 
activity is generally identified as being either mild (approximately four bloody stools a 
day with minimal systemic toxicity), moderate (four to six bloody stools), and severe 
(more than six bloody stools a day). In addition to the increased bloody stools observed in 
patients with severe UC, there are endo-organ signs of systemic toxicity such as fever, 
anemia, tachycardia, and increased erythrocyte sedimentation rate (ESR) (Baumgart & 
Sandborn, 2007). 
 Patients with CD typically experience right lower quadrant abdominal pain. They 
can also develop obstruction due to the transmural nature of the inflammation in the wall 
of the intestine. Hematochezia, or the presence of blood in the stool, is less prominent in 
patients with CD than in those presenting with UC (Fakhoury, Negrulj, Mooranian, & Al-
Salami, 2014). Inflammation in CD patients can extend anywhere from the mouth to the 
anus. Previous studies have recorded the presence of the disease in the terminal ileum in 
47% of cases, the colon in 28% of cases, the ileocolonic region in 21% of cases, and the 
upper GI tract in 3% of cases (Baumgart & Sandborn, 2007). In the clinical setting, CD 
disease activity is identified as mild to moderate (abdominal tenderness, weight loss, 
toleration of oral medication) and moderate to severe (more prominent weight loss, 






Figure 3. UC versus CD colon. Longitudinal ulcers, barely intact mucosa. (Above) UC 
transverse colon and descending colon. Loss of vascular pattern, irregular surface, 
ulcerations, hemorrhage. (Below) CD terminal ileum and sigmoid colon. Friability, loss 
of vascular pattern, ulcerations, patchy inflammation, cobblestone pattern. (Baumgart & 
Sandborn, 2007). 
 
 Other common gastrointestinal symptoms seen in IBD patients include proctitis, 
left sided colitis, and pancolitis (Danese & Fiocchi, 2011). In addition to the numerous 
symptoms originating in the GI tract, there are other many extraintestinal complications 
of IBD involving but not limited to the musculoskeletal, dermatologic, pulmonary, renal, 
and ocular systems. Psoriatic arthritis is a common dermatologic complication of IBD, 
and it is more commonly seen in patients with colonic CD than those patients with UC 
and pancolitis. Previous studies showed that psoriatic lesions contain high concentrations 
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of TNF-a, comparable to levels observed in involved intestinal segments in patients with 
CD (Levine & Burakoff, 2011). Malnutrition and nutritional deficiencies, including low 
vitamin D levels, are also common in patients with IBD due to either disease-related 
anorexia or a relative inability of the compromised GI tract to efficiently absorb nutrients 
from the diet (Ananthakrishnan, 2015). More than 50% of CD patients present with folate 
and vitamin D deficiency, and more than 50% of UC patients present with iron deficiency 
(Seyedian, Nokhostin, & Malamir, 2019). 
 
Diagnosis 
 Overlapping clinical symptoms can make it difficult to differentiate patients with 
IBD from those with other immunologic and autoimmune diseases more definitively. For 
example, patients with IBD and Irritable Bowel Syndrome experience many of the same 
GI symptoms (El-Matary, Dupuis, & Sokoro, 2015). Nonetheless, it is essential for 
clinicians to reach an accurate diagnosis of CD or UC before the initiation of 
pharmacologic therapy or consideration of surgical options (Guindi & Riddell, 2004). 
Current medical examinations used to diagnose IBD include fecal testing, complete blood 
count (CBC), barium x-ray imaging, upper endoscopy, colonoscopy, and magnetic 
resonance imaging (MRI) (Seyedian, Nokhostin, & Malamir, 2019). The information 
obtained from these tests will help to identify the location, severity, and extent of 
inflammation in patients with known or suspected CD or UC (Danese & Fiocchi, 2011; 
Rufo & Bousvaros, 2007). Capsule endoscopy, which involves the patient swallowing a 
micro-camera encased in a capsule, now allows clinicians to visualize portions of the 
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small intestine that have been previously unreachable using standard endoscopic 
techniques (Fakhoury, Negrulj, Mooranian, & Al-Salami, 2014). Imaging modalities like 
MRI provide cross-sectional imaging data that is particularly useful to identify and assess 
intestinal complications of IBD, including obstructions, abscesses, or fistulae (Fakhoury, 
Negrulj, Mooranian, & Al-Salami, 2014). 
 Endoscopic and colonoscopic evaluations involve the insertion of a camera 
through either the mouth or the anus to allow direct observation of the GI tract. These 
procedures enable clinicians to assess for the presence and extent of acute or chronic 
mucosal inflammation in the intestine (Fakhoury, Negrulj, Mooranian, & Al-Salami, 
2014). The information obtained from a direct microscopic assessment of biopsies 
obtained during upper endoscopic and colonoscopic studies is currently the most 
definitive way to diagnose IBD and to distinguish between patients with CD from those 
with UC.  
 Laboratory blood tests are also used by clinicians to help assess disease and 
monitor disease activity in patients with IBD, and these include C-reactive protein (CRP), 
ESR, and white blood cell (WBC) (Fakhoury, Negrulj, Mooranian, & Al-Salami, 2014). 
While useful, ESR and CRP levels are not definitive assessments for GI disease. ESR 
measures the rate at which erythrocytes (red blood cells) fall in a given sample of blood. 
Typically, red blood cells have a slow rate of sedimentation, resulting in a low ESR. 
However, in the context of active inflammation, including that seen in patients with 
active IBD, the ESR is elevated due to increased concentrations of negatively charged 
acute phase reactants, including fibrinogen. These acute-phase reactants attach to RBC 
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and hasten their fall through the serum, resulting in an increased ESR (Harrison, 2015). 
CRP is a protein produced by the liver in response to IL-6 that has been released 
systemically by damaged or stressed immune cells. CRP participates in the activation of 
the complement cascade and subsequent phagocytosis of foreign pathogens (Harrison, 
2015). Despite their utility, ESR and CRP are non-specific markers of inflammation in 
the body and cannot be used as the sole diagnostic tool for IBD (Harrison, 2015). 
 
Inflammatory Biomarkers of IBD 
 Biomarkers fall under the broad category of medical signs and indicate the 
medical state of a patient from an objective standpoint. According to the Biomarkers 
Definitions Working Group at the National Institute of Health, biomarkers are “a 
characteristic that is objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention” (Strimbu & Tavel, 2011). Additionally, the World Health Organization 
(WHO) defines biomarkers as “any substance, structure, or process that can be measured 
in the body or its products and influence or predict the incidence of outcome or disease” 
(Strimbu & Tavel, 2011). Biomarkers are different from medical symptoms, which are 
restricted to subjective indications of an illness that is perceived by the patient or 
physician themselves (Strimbu & Tavel, 2011). In contrast, biomarkers must be 
objective, accurate, and reproducible. Biomarkers can be used to help with the diagnosis 
of a disease. However, they do not always directly correlate with a patient’s symptoms 
and overall wellbeing (Strimbu & Tavel, 2011). Just as our knowledge of the human body 
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is limited and constantly changing, the application of biomarkers is not restricted to 
current boundaries and must be under continuous re-evaluation (Strimbu & Tavel, 2011). 
Biomarkers studied in patients with IBD include Anti-Saccharomyces cerevisiae 
antibodies (ASCA), fecal calprotectin (FC), and lactoferrin (Lf).  
 ASCA are antibodies against a specific yeast strain, Saccharomyces Cerevisiae, a 
commonly detected fungi in human feces and most likely originates from food 
(Kvehaugen, Aasbrenn, & Farup, 2017). Antibodies can be useful as biomarkers because 
they target specific foreign material in the body and can help determine if a bacteria or 
virus is responsible for the infection or disease. ASCA is currently the most well-known 
serologic biomarker and is a promising non-invasive diagnostic tool for use in the 
assessment of patients with IBD. ASCA titers are typically higher in patients with CD, 
relative to those measured in patients with UC (Duman et al., 2018). For example, studies 
showed that elevated serum ASCA levels are measurable in approximately 60-70% of 
patients with CD (Kansal et al., 2019),10-15% of patients with UC, and only 0-5% of 
healthy controls (Walker et al., 2004).  
 Calprotectin is a 36kDa member of the S100 protein family and originates from 
neutrophils (Ayling & Kok, 2018). It is a calcium and zinc binding protein that accounts 
for approximately 60% of soluble proteins in neutrophil cytosol (Bjarnason, 2017). 
Calprotectin has degradation resistant characteristics that make it stable in feces at room 
temperature (Bjarnason, 2017) and and fecal calprotectin (FC) concentration that is an 
objective proxy for the presence and number of neutrophils present in a clinical sample, 
and it will be elevated in the context of active inflammation (Bjarnason, 2017). 
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Furthermore, studies show that serial elevation of FC suggests IBD progression 
(Seyedian, Nokhostin, & Malamir, 2019).  
 Fecal lactoferrin (Lf) is an 80kKa glycosylated protein containing approximately 
700 amino acids (Siqueiros-Cendon et al., 2014). Lf is an iron binding protein of the 
transferrin family and is found in high concentrations in biological fluids and mammalian 
milk (Siqueiros-Cendon et al., 2014). Like FC, Lf originates from neutrophils and is 
released during inflammation into the bloodstream and tissues (Siqueiros-Cendon et al., 
2014). FC and Lf are both derived from neutrophils and possess direct anti-microbial 
properties (Siqueiros-Cendon et al., 2014). FC and Lf be used as biomarkers of IBD 
because their levels increase in the context of increased gastrointestinal inflammation 
(Siqueiros-Cendon et al., 2014). 
 
Treatments and Medications 
 There is no existing cure for patients with IBD, and current treatment strategies 
focus on reducing IBD symptoms, decreasing mucosal inflammation, and the prevention 
of disease-related complications. (Fakhoury, Negrulj, Mooranian, & Al-Salami, 2014). 
Deciding which medication(s) and treatment plan are most appropriate for a patient with 
IBD is complex and requires knowledge of the progression of a patient’s IBD, underlying 
diagnosis (CD, UC, IC), location and extent of disease, and disease history (Rufo & 
Bousvaros, 2012). Medications used in the management of patients with IBD include 
corticosteroids, immunomodulators (Papamichael et al., 2019), antibiotics, and anti-TNF 
agents. Drugs such as aminosalicylates, mercaptopurine, methotrexate, and infliximab are 
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often used as maintenance therapies (Rufo & Bousvaros, 2012). However, many 
pharmaceutical agents have numerous associated side effects, including headache, 
diarrhea, nausea, and skin rashes (Fakhoury, Negrulj, Mooranian, & Al-Salami, 2014).  
 Infliximab, commercially known as Remicade, is a synthetic chimeric monoclonal 
IgG1 antibody that was the first-ever anti-TNF agent approved for use in the management 
of patients with IBD. Infliximab has a half-life of approximately 14 days. Patients 
typically receive loading doses at time 0, 2-weeks, and 6-weeks, and then are maintained 
with infusions delivered every 4-8 weeks after that (Papamichael et al., 2019). As an anti-
TNF agent, the primary purpose of infliximab in the treatment of patients with IBD is to 
neutralize TNF-a’s pro-inflammatory activity by triggering a Th2-mediated response that 
reduces Th1’s inflammatory effects and produces anti-inflammatory cytokines such as 
IL-4, IL-5, IL-6 and IL-10 (Fakhoury, Negrulj, Mooranian, & Al-Salami, 2014). 
Infliximab is used to help CD and UC patients enter clinical remission (Magro & Portela, 
2012). Studies showed that in a sample controlled group, more patients on infliximab 
were able to maintain clinical remission and mucosal healing than those randomized to 
placebo therapy (Rutgeerts et al., 2005).  
 
Impact of IBD in Pediatric Patients  
Quality of health care (QoC) has become an essential aspect of disease monitoring 
and treatment, as well as disease prevention. Chronic multisystem diseases like IBD can 
impact profoundly a patient’s ability to participate in regular age-appropriate academic, 
social, and athletic activities. This can reduce overall health-related quality of life 
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(HRQoL) (Eijk et al., 2004), which is defined as the measure of a patient’s mental health 
status as it pertains to how their disease affects them physically, mentally, and 
emotionally (Abdovic et al., 2013). HRQoL considers medical and psychological data 
collected along five dimensions, including disease activity, psychologic status, coping 
patterns, social support, and stressful life events (Eijk et al., 2004). It is especially 
important to assess QoL in pediatric patients as an active chronic disease can have a 
significant impact on a child’s mental growth and development. 
 The IMPACT-III questionnaire is a self-reporting metric that contains 35 IBD-
specific questions focused along six domains: Bowel Symptoms (7 questions), Systemic 
Symptoms (3 questions), Social Functioning (12 questions), Body Image (3 questions), 
Treatment/Intervention (3 questions), and Emotional Functioning (7 questions) (Abdovic 
et al., 2013). All answers in the IMPACT-III form are graded on a 5-point Likert scale 
ranging from 1 to 5 points, and the total score ranges from 35 to 175 points, with higher 
scores suggesting a better quality of life (Abdovic et al., 2013). Lastly, the questionnaire 
ends with a final comment section in which patients may comment on anything they wish 











 Inflammatory biomarkers are promising tools for use in the diagnosis and interval 
assessment of patients with known or suspected IBD. The first objective of this study is 
to measure changes in biomarker levels in patients with CD and UC who are starting or 
have been receiving Infliximab (Remicade) treatment. Serum and fecal biomarkers 
include ASCA, Lactoferrin, Calprotectin, and cytokines. The second objective of this 
study is to investigate further the relationship between changes in these biomarker levels 
and the clinical, biochemical, and endoscopic outcome parameters. In addition to the 
serum and fecal samples, the study assesses the long-term psychological and physical 









 This study was approved by the Boston Children’s Hospital Institutional Review 
Board (IRB) under the name “Serial Fecal Biomarker Measurements Predict Response to 
Biologic Therapy in Children with IBD” (protocol ID IRB-P00023092). The study is a 
prospective longitudinal cohort study involving pediatric patients 21 years or younger, 
receiving the anti-TNF agent, Infliximab (Remicade). This is a multicenter study that 
takes place in parallel at Boston Children’s Hospital in Boston and Riley Children’s 
Hospital in Indianapolis. 
 Eligible participants diagnosed with CD, UC, or IC, and receiving infliximab 
infusions, were eligible to participate in this study. Patients were first approached in the 
Center for Ambulatory Therapy & Clinical Research (CAT/CR), consented, and enrolled 
in the study. Participants subsequently provided serum and stool sampled during each of 
their next six consecutive infliximab infusion appointments. 
Patients were excluded from the study if their primary GI providers did not give 
consent to their participation, if patients were unwilling to provide serum or stool 
samples, or if patients chose not to consent to enrollment.  
 
Patient Population 
  Eligible patients were categorized by diagnosis (CD, UC, IC) and further 
separated based on Infliximab history. The first subcategory for Infliximab history was 
patients in their induction phase, which means that they had received either their first, 
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second, or third Infliximab dose. The second subcategory was patients in their post-
induction phase but on Infliximab for less than six months, meaning their participation in 
the study occurred less than six months from their induction phase. The last subcategory 
was patients in their post-induction phase and on Infliximab for over one year.  
 The study required 50 IBD patients from each research site. Furthermore, the 
study called for a total of 30 CD patients (10 induction, 10 <6 months, 10 >1 year), 15 
UC patients (5 induction, 5 <6 months, 5 >1 year), and 5 IC patients (from any 
subcategory). Currently, we have a total of 45 IBD participants with a distribution of 27 
CD, 17 UC, and 1 IC. The CD category includes 7 induction patients, 10 less than six 
months patients, and 10 post one year patients. The UC category includes 6 induction 
patients, 5 less than six months patients, and 6 patients that were diagnosed with CD 
more than one year previous. The IC category includes 1 post one year patient.  
 
Patient Screening and Recruitment 
 PowerChart, an electric medical record (EMR) database, was used to collect any 
protected health information (PHI), including patient demographics, IBD history, location 
of infusion site, and Infliximab stage. All assessed patients were noted in a separate list 
for reference purposes. Once a patient was deemed eligible for the study, their primary GI 
provider was contacted to ask for permission to approach the patient. If the GI provider 
said no, the patient was not approached. If the GI provider said yes, the patient was then 
approached by the Research Study Coordinators during the next Infliximab infusion 
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appointment at the CAT/CR at either the Longwood or Waltham campus of Boston 
Children’s Hospital.  
 The Research Study Coordinators first introduced the study and described the 
long-term goals of the project. Then, the Research Study Coordinators continued to 
explain the study protocol, procedures, and instructions for patient participation. 
Participating patients were followed for the next six of their Infliximab infusion 
appointments at their respective CAT/CR sites following the day of consent and 
enrollment. At each appointment, the Research Study Coordinator collected a total of 
three things: a 5mL blood sample drawn at the CAT/CR, a stool sample provided by the 
patient (1-2 tablespoons, obtained before the appointment), and an IMPACT-III form that 
was filled out at the time of the appointment. The patient was compensated $35 for every 
stool sample brought in for the study. Any questions or concerned were addressed at that 
time.  
If the patient and the family wished to participate, they were given six stool 
collection kits and the physical consent form to sign. Each stool kit consisted of a stool 
hat, stool specimen cup, wooden tongue depressor to use for stool transfer, latex gloves, 
protective mask, and a biohazard bag. Parents signed the form if the patient was under the 
age of 18, and patients who were 18 and older were able to sign as adult participants. The 
patient’s family was given a copy of the consent form to take home, and the original copy 
was kept at the hospital. Each consented patient was given their own unique BCH ID 




Sample Processing and Shipment 
 Fecal and blood samples that were obtained by Research Study Coordinators were 
process in the Snapper Lab in the Enders Buildings at Boston Children’s Hospital 
Longwood campus. Blood samples were spun in a centrifuge at 25°C and 3000 rpm for10 
minutes. The top serum layer was obtained using a pipette and divided into three 1mL 
aliquots in Thermo ScientificÔ Nalgene Cyrogenic Tubes. Stool samples were divided 
into three aliquots under the fume hood. All processed tubes were labeled with the unique 
BCH ID of the patient and stored in a -80°C freezer.  
 Fecal and serum samples were shipped every two to three months to TECHLABâ 
Inc. in Blacksburg, Virginia for biomarker analysis. All samples were shipped in a 
Styrofoam shipping box with dry ice to keep the samples frozen. A list of all the fecal and 




All data from active participants of the study were collected and recorded in the 
Research Electronic Data Capture (REDCap) site. The site allows research data to be 
recorded and managed by other participating team members. Data from this project was 
shared with the research team at Riley Children’s Hospital. Therefore, all protected health 
information (PHI) of Boston Children’s Hospital patients was excluded from the 
REDCap data. The components of the REDCap reports include: demographics, 
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medications, disease location, Paris classification, infusion data, IMPACT-III, enrollment 











































































 An initial group of 672 consecutive patients was assessed for eligibility based on 
the inclusion criteria involving age, diagnosis, and Remicade status (287 from 
PowerChart, 39 from Pathology cases, 346 from Remicade Visit lists). 58 patients 
consented and enrolled in the study. The demographic data of the entire patient 
population is shown in Table 2. The breakdown of diagnosis and Remicade status of 
recruited patients is presented in Table 3. 
 
 






Table 3. Patient Population: Table of recruited patient population by diagnosis and 
Remicade phase (n=58).  
 
 
A total of 58 patients have been enrolled, and 13 of these patients subsequently 
dropped out of the study. Out of these 13 patients, 7 patients chose to withdraw from the 
study due to personal reasons, 2 patients were lost for follow-up, and 4 patients were 
withdrawn from the study for lack of stool samples. Currently, 45 patients in the study 
are still active or have completed the study (27 CD, 17 UC, and 1 IC). A flowchart of all 
active and inactive patients in the study, presenting the breakdown of patient distribution 







Figure 14. Recruited Patient Population: Flow chart of recruited patients based on 




















































































































































































































































































































































































































Biomarker Levels at Baseline Infusion  
 Serum and fecal samples were collected from a total of 54 patients (35 CD, 18 
UC, and 1 IC). A total of 28 serum samples were collected from 15 patients with CD, 12 
patients with UC, and 1 patient with IC. A total of 20 fecal samples were collected from 
10 patients with CD, 9 patients with UC, and 1 patient with IC. A total of 54 lab samples 
were collected from 35 patients with CD, 18 patients with UC, and 1 patient with IC. 
Serum samples were used to measure ASCA and lactoferrin levels. Fecal samples were 
used to measure ASCA, lactoferrin, calprotectin, hemoglobin, IL1-a, and IL1-b levels. 
Lab samples were used to measure ESR and CRP levels.  
 There was no significant difference in biomarker levels between patients with CD 
and those with UC at the time of their baseline infusion (p>0.10). The difference in serum 
ASCA levels between patients with CD and those with UC had a p-value of 0.60, and the 
difference in fecal ASCA levels between patients with CD and those with UC had a p-
value of 0.30. Statistical analysis was not used to analyze data for the IC category 
because there was only one patient. The biomarker levels for CD, UC, and IC patients at 
baseline infusion are summarized in Table 4.  
According to the data illustrated in Table 4, the number of serum samples differs 
from the number of stool samples given. Throughout the study, some patients were only 
able to provide either serum or stool samples, and therefore the number of submitted 
serum and stool samples varied. Additionally, some samples were labeled “QNS” 
(quantity not sufficient), which means that the quantity of specimen received by the lab 




Table 4. Baseline Data.  This table presents biomarker levels for CD, UC, and IC 
patients at baseline infusion. The biomarker levels were taken from serum, fecal, and lab 
samples. (a) CD Baseline Data. The table shows data for patients with CD at baseline 
infusion. (b) UC Baseline Data. The table shows data for patients with UC at baseline 




Serum and Fecal ASCA Levels by Infusion  
 Changes in baseline serum ASCA levels for patients with CD, UC, and IC 
through infusion 5 are shown in Figure 15. Serum ASCA levels for patients with CD 
were higher at baseline and infusion 1, then they decreased for infusions 2 to 5. There 
was a slow increase in serum ASCA levels for patients with UC from baseline to infusion 
3 then a subsequent decrease for infusions 4 and 5. Overall, infusions 4 and 5 had low 
levels of serum ASCA for patients with either CD or UC. The difference in serum ASCA 
levels between patients with CD and those with UC was not significant for any infusions. 
The biggest difference in serum ASCA levels between CD and patients with UC occurred 
in infusion 3 (p=0.23). An optical density of 0.08 was the borderline for determining high 
serum ASCA levels. A total of 3 Patients with CD had high serum ASCA levels: 0.11 at 
baseline and 0.117 and 0.125 at infusion 1. Two Patients with UC had high serum ASCA 
levels: 0.096 at infusion 2 and 0.094 at infusion 3.  
 Fecal ASCA levels for patients with CD, UC, and IC from baseline to infusion 5 
are presented in Figure 16. Fecal ASCA levels were highest at baseline and infusion 1 
for patients with CD, and at infusion 4 for patients with UC. The difference in serum 
ASCA levels between patients with CD and those with UC were not significant for any 
infusions. The biggest difference in fecal ASCA levels between patients with CD and 
patients with UC occurred at baseline (p=0.30). An optical density of 0.110 was used to 
determine high fecal ASCA levels. Two patients with CD had high fecal ASCA levels: 
0.597 at baseline and 0.181 at infusion 1. One UC patient had a high fecal ASCA level of 
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0.114 at infusion 4. Out of the 3 patient groups (CD, UC, and IC), the IC patient 
consistently had the lowest serum and fecal ASCA levels.   
 
Figure 15. Serum ASCA Levels by Infusion. Figure shows serum ASCA levels for CD, 
UC, and IC patients from baseline to infusion 5.  
 
 
Figure 16. Fecal ASCA Levels by Infusion. Figure shows fecal ASCA levels for CD, 
UC, and IC patients from baseline to infusion 5.  
	
39 
Serum and Fecal Lactoferrin Levels by Infusion 
Serum lactoferrin levels for patients with CD, UC, and IC from baseline to 
infusion 5 are shown in Figure 17. Serum lactoferrin levels were highest at infusion 4 for 
patients with both CD and UC. Levels were the lowest at infusion 2 for patients with CD 
and infusion 5 for patients with UC. Patients with CD and UC had similar levels of serum 
lactoferrin at baseline, infusion 1, and infusion 3. Serum lactoferrin levels between 
patients with CD and those with UC were significantly different at infusion 2 (p=0.042). 
Additionally, serum lactoferrin levels for patients with UC were significantly different 
from infusion 4 to 5 (p=0.098). Borderline values to indicate high levels of serum 
lactoferrin are unknown. 
 Fecal lactoferrin levels for patients with CD, UC, and IC from baseline to infusion 
5 are presented in Figure 18, fecal lactoferrin levels above 7.25 µg/g are considered high. 
Fecal lactoferrin levels were the highest at infusion 1 for patients with both CD and UC. 
The difference in fecal lactoferrin levels between patients with CD and those with UC 
were not significant for any infusions. The biggest difference in fecal lactoferrin levels 
between patients with CD and those with UC occurred at infusion 1 (p=0.59). According 
to the figure, a total of 16 patients with CD had high fecal lactoferrin levels at baseline 
(30, 83, 15, 17, 97, and 21 µg/g), infusion 1 (74, 15, 30, 366, and 180 µg/g), infusion 2 
(29, 37, and 80 µg/g), and infusion 3 (15 and 118 µg/g). A total of 7 patients with UC had 
high fecal lactoferrin levels at baseline (351 and 121 µg/g), infusion 1(8, 834, and 12 
µg/g), infusion 3 (9 µg/g), and infusion 4 (208 µg/g). Fecal lactoferrin levels for the 




Figure 17. Serum Lactoferrin Levels by Infusion. Figure shows serum lactoferrin 
levels for CD, UC, and IC patients from baseline to infusion 5. Serum lactoferrin levels 
between CD and UC patients are significant at infusion 2 (p<0.05). Serum lactoferrin 
levels for UC patients at infusions 4 and 5 are significant (p<0.10).  
 
 
Figure 18. Fecal Lactoferrin Levels by Infusion. Figure shows fecal lactoferrin levels 
for CD, UC, and IC patients from baseline to infusion 5.  
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Fecal Calprotectin Levels by Infusion 
 Fecal calprotectin levels for patients with CD, UC, and IC from baseline to 
infusion 5 are shown in Figure 19. Fecal calprotectin levels were highest at infusion 3 for 
patients with CD, infusion 4 for patients with UC, and infusion 1 for the single IC patient. 
Fecal calprotectin levels for patients with UC were consistently low from baseline to 
infusion 5, except for two spikes at infusion 1 and 4. Two samples from were determined 
QNS by the lab and therefore were not a part of this analysis. The difference in fecal 
calprotectin levels between patients with CD and those with UC were not significant for 
any infusions. The biggest difference in fecal calprotectin levels between patients with 
CD and UC occurred at infusion 4 (p=0.3663).  
Fecal calprotectin levels above 50-120 µg/g are considered borderline high. Six 
patients with CD had high fecal calprotectin levels at baseline (73 µg/g), infusion 1 (55, 
55, and 113 µg/g), as well as at infusion 2 (95 and 113 µg/g). Five patients with UC had 
high fecal calprotectin levels at baseline (52, 73, and 108 µg/g), at infusion 4 (78 µg/g), 
and again at infusion 5 (60 µg/g). One patient with IC had high fecal calprotectin levels 
of 73 µg/g at infusion 1. Fecal calprotectin levels above 120 µg/g are considered 
abnormally high. A total of 14 patients with CD had abnormally high fecal calprotectin 
levels at baseline (144, 237, 174, 591, and 245 µg/g), at infusion 1 (666, 168, 173, 1142, 
and 572 µg/g), and at infusions 2 (245 and 603 µg/g), and infusions 3 (209 and 935 
µg/g). There was one CD patient with a 466% increase in fecal calprotectin from baseline 
to infusion 1. Three patients with UC had abnormally high fecal calprotectin levels at 




Figure 19. Fecal Calprotectin Levels by Infusion. Figure shows fecal calprotectin 
levels for CD, UC, and IC patients from baseline to infusion 5.  
 
Fecal Hemoglobin Levels by Infusion 
 Fecal hemoglobin levels for patients with CD, UC, and IC from baseline to 
infusion 5 are presented in Figure 20. Fecal hemoglobin levels for patients with CD were 
consistently low from baseline to infusion 5, with the highest level of 11.25 µg/g at 
infusion 1. The UC patient group had a fecal hemoglobin level of zero for infusions 2, 3, 
and 5. The highest level of fecal hemoglobin for patients with UC was at infusion 1. The 
IC patient had a fecal hemoglobin level of zero from baseline to infusion 2.  
The difference in fecal hemoglobin levels between patients with CD and those 
with UC were not significant for any infusions. The greatest difference in fecal 
hemoglobin levels between patients with CD and those with UC occurred at infusion 1 
(p=0.2423). Fecal hemoglobin levels above 15 µg/g were considered high. Three patients 
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with CD had high fecal hemoglobin levels at baseline (18 µg/g), infusion 1 (22, 77, and 
30 µg/g), and infusion 3 (36 µg/g). Three patients with UC had high fecal hemoglobin 
levels at baseline (405 and 59 µg/g), infusion 1 (3410 µg/g), and infusion 4 (77 µg/g). 




Figure 20. Fecal Hemoglobin Levels by Infusion. Figure shows fecal hemoglobin 
levels for CD, UC, and IC patients from baseline to infusion 5.  
 
Fecal IL1-a Levels by Infusion 
 Fecal IL1-a levels for patients with CD, UC, and IC from baseline to infusion 5 
are shown in Figure 21. The CD and UC groups showed similar patterns of increased and 
then decreased fecal IL1-a levels from baseline to infusion 5. Both groups had an 
average fecal IL1-a level of zero at infusion 5. The highest IL1-a level for patients with 
UC occurred at infusion 4. The highest IL1-a level for the single IC patient occurred at 
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baseline. One sample was determined QNS by the lab and therefore were not a part of 
this analysis.  
The difference in fecal IL1-a levels between patients with CD and those with UC 
was not significant for any infusion. The biggest difference in fecal IL1-a levels between 
patients with CD and those with UC occurred at infusion 4 (p=0.5460). Fecal IL1-a 
levels above 2051 pg/g were considered to be high. Two patients with CD had high fecal 
IL1-a levels at infusion 1 (11012 pg/g) and infusion 3 (2068 pg/g). Three patients with 
UC had high fecal IL1-a levels at infusion 1 (5926 pg/g), infusion 2 (3124 pg/g), and 




Figure 21. Fecal IL1-a Levels by Infusion. Figure shows fecal IL1-a levels for CD, 




Fecal IL1-b Levels by Infusion 
 Fecal IL1-b levels for patients with CD, UC, and IC from baseline to infusion 5 
are presented in Figure 22. One sample was deemed QNS by the lab and therefore were 
not a part of this analysis. The difference in fecal IL1-b levels between patients with CD 
and those with UC was not significant for any infusion. The biggest difference in fecal 
IL1-b levels between patients with CD and those with UC occurred at infusion 4 
(p=0.4226). Fecal IL1-b levels above 101 pg/g were considered to be high. Four patients 
with CD had high fecal IL1-b levels at infusion 1 (163 and 530 pg/g) and infusion 3 (367 
and 37757 pg/g). Six patients with UC had high fecal IL1-b levels at baseline (5937 
pg/g), infusion 1 (1848 and 1067 pg/g), infusion 3 (483 and 1009 pg/g), and infusion 4 
(91541 pg/g).  
 
 
Figure 22. Fecal IL1-b Levels by Infusion. Figure shows fecal IL1-b levels for CD, 
UC, and IC patients from baseline to infusion 5.  
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ESR by Infusion 
 ESR values for patients with CD, UC, and IC from baseline to infusion 5 are 
presented in Figure 23. There was no distinct increase or decrease in ESR levels 
throughout the study for any of the three patient groups. ESR levels for patients with CD 
were significantly higher than levels measured in patients with UC at infusion 1 
(p=0.0618). ESR levels for patients with UC were significantly higher than levels for 
patients with CD at infusion 4 (p=0.1009). Additionally, ESR levels for patients with CD 
decreased significantly from infusion 1 to 2 (p=0.0595). ESR levels above 35 mm/hr 
were considered to be high. A total of six patients with CD were identified as having high 
ESR levels at baseline (38 and 39 mm/hr), infusion 1 (43, 38, and 52 mm/hr), and 
infusion 3 (40 mm/hr). 
 
 
Figure 23. ESR by Infusion. Figure shows ESR levels for CD, UC, and IC patients from 
baseline to infusion 5. ESR levels between CD and UC patients are significant at infusion 
1 (p<0.10) and infusion 4 (p<0.10). ESR levels for CD patients are significant between 
infusions 1 and 2 (p<0.10).  
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CRP by Infusion  
 CRP values for patients with CD, UC, and IC from baseline to infusion 5 are 
shown in Figure 24. CRP levels for patients with CD were significantly higher than 
levels for patients with UC at baseline (p=0.0507) and at infusion 1 (p=0.0314). CRP 
values for patients with CD significantly decrease from infusion 1 to 2 (p=0.0405). CRP 
levels above 0.5 mg/dL are considered to be high. A total of 12 patients with CD had 
high CRP values at baseline (0.86, 1.82, 1.34 and 1.03 mg/dL), infusion 1 (0.74, 0.60, 
0.99, and 0.92 mg/dL), infusion 3 (1.31 and 5.62 mg/dL), infusion 4 (1.66 mg/dL), and 
infusion 5 (0.70 mg/dL). One CD patient had an 18,633% increase in CRP levels from 
infusions 2 to 3. One patient with UC had an 8,116% increase in CRP levels from 
infusions 3 to 4.  
 
 
Figure 24. CRP by Infusion. Figure shows CRP levels for CD, UC, and IC patients 
from baseline to infusion 5. CRP levels between CD and UC patients are significant at 
baseline (p<0.05) and infusion 1 (p<0.05). CRP levels for CD patients are significant 
between infusions 1 and 2 (p<0.05).  
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IMPACT-III Scores by Infusion  
 An IMPACT-III questionnaire was given to each patient at every infusion. Each 
IMPACT-III form has 35 questions, and the total score ranges from 35 to 175. Higher 
scores indicate a better quality of life. The average IMPACT-III scores for each category 
in the questionnaire for CD, UC, and IC patients throughout the infusions are presented in 
Table 5. The total IMPACT-III scores for patients with CD, UC, and IC from baseline to 
infusion 5 are summarized in Figure 25. The total mean score at baseline was 137.8 ± 18 
for patients with CD and 140.3 ± 15.4 for patients with UC. There was no statistical 
significance between the two scores at baseline (p=0.63). At Infusion 4, the total score for 
patients with UC was significantly higher than that of patients with CD (p=0.05).  
 
 
Figure 25. Total IMPACT-III Scores. This figure summarizes the total IMPACT-III 
Questionnaire scores for CD, UC, and IC patients from baseline to infusion 5. There is a 
significant different in total IMPACT-III scores between CD and UC patients at infusion 





Table 5. IMPACT-III Scores: Table of IMPACT-III Questionnaire scores for CD, UC, 
and IC patients. (a) CD Scores. Table presents mean ± SD scores from baseline to 
infusion 5 for CD patients. (b) UC Scores. Table presents mean ± SD scores from 
baseline to infusion 5 for UC patients. (c) IC Scores. Table presents mean ± SD scores 













 Existing data have demonstrated that serum and fecal inflammatory biomarkers 
are promising diagnostic tools for the diagnosis and interval assessment of patients with 
known or suspected IBD. The main goal of this study was to investigate the relationship 
between the changes in serum and fecal inflammatory biomarkers and the clinical, 
endoscopic, and mental wellbeing of patients. The severity of their GI symptoms was 
measured using serum and fecal samples, and their quality of life was measured using the 
IMPACT-III questionnaire. The primary objective was to measure changes in 
inflammatory biomarker levels such as ASCA, lactoferrin, calprotectin, and cytokines in 
CD, UC, and IC patients at varying stages with the anti-TNF therapy, infliximab 
(Remicade). The second objective was to observe how these changes in biomarker levels 
can be used to assess disease activity in IBD patients and assess Remicade effectiveness.  
 This is an ongoing longitudinal, multicentered project. As such, the data set is 
incomplete, and further progression of the study is needed before a more comprehensive 
analysis of the data can be completed. We predict that with the completion of patient 
recruitment and collection of more serum and fecal samples, we will be able to better 
determine better the ability of inflammatory biomarkers to reflect IBD progression in 
patients. Additionally, the analysis of the data collected by the IC group (n=1) was not 
included because since there was only one participant in the study, the biomarker values 
for this patient are not representative of the overall IC group.  
 The mean serum and fecal ASCA levels in patients with CD decreased from 
baseline to infusion 5. However, serum ASCA levels for patients with UC increased 
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infusion 3 and then decreased. Serum and fecal ASCA levels were higher in patients with 
CD than those with UC at baseline. Additionally, there were more patients with CD 
identified as having high serum and fecal ASCA levels than patients with UC. Previous 
studies have shown that ASCA is more likely to be higher in patients with CD than in 
those with UC, and the data we have so far align with previous studies. One patient with 
CD had to withdraw from the study after their first infusion due to a loss of response to 
Remicade. This patient had high serum ASCA levels at baseline and infusion 1 as well as 
high levels of fecal calprotectin and fecal lactoferrin. According to clinical notes, this 
patient was in the middle of an IBD flare with increased bloody stools.  
A second patient with CD had a continual decrease in serum ASCA levels from 
baseline to infusion 4, the longest continuous sample collection from a patient in the 
serum ASCA category. Lastly, the highest level of fecal ASCA in any of the three 
diagnostic categories came from baseline measurement obtained from a patient with CD. 
This patient also had high fecal calprotectin and lactoferrin. All the evidence suggests 
that serum and fecal ASCA are promising biomarkers for inflammation.  Fecal ASCA 
levels increase during heightened intestinal disease activity in patients with CD. 
However, there were no significantly different serum or fecal ASCA levels between 
patients with CD and those with UC for any of the infusions, and so a conclusive analysis 
cannot be made in using ASCA to differentiate between CD and UC diagnosis.  
 Serum lactoferrin levels were higher in patients with CD than in those measured 
in patients with UC at baseline, but the median serum lactoferrin levels did not differ 
substantially. On the other hand, mean fecal lactoferrin levels for patients with UC were 
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higher than that of patients with CD, but the median fecal lactoferrin level for patients 
with CD was higher than that observed in patients with UC. This suggests that patients 
with UC had lower fecal lactoferrin levels overall, but there were a few outliers with 
exceptionally high fecal lactoferrin levels. Serum lactoferrin levels for patients with UC 
were significantly higher than those of patients with CD at infusion 2, and serum 
lactoferrin levels for both patients with CD and those with UC were the highest at 
infusion 4. There was no significant difference in fecal lactoferrin levels between patients 
with CD and those with UC from baseline to infusion 5. However, fecal lactoferrin levels 
for both patients with CD and those with UC were the highest at infusion 1. This suggests 
that Remicade might be effective in suppressing inflammatory symptoms in the early 
infusion stages of the treatment, but patients are still susceptible to IBD relapse.  
 Fecal calprotectin levels were higher in patients with CD and those with UC from 
baseline to infusion 3. Additionally, there were more patients with CD identified as 
having abnormally high fecal calprotectin levels than patients with UC (5 CD and 1 UC). 
However, there were no significant differences in fecal calprotectin levels between 
patients with CD and UC from baseline to infusion 5. Fecal calprotectin levels for 
patients with UC increased from baseline to infusion 1, decreased from infusions 2 to 3, 
peaked at infusion 4, and finally decreased again at infusion 5. This was the same pattern 
observed in patients with UC for fecal lactoferrin. We also found that patients with high 
fecal calprotectin levels are more likely to have high fecal lactoferrin levels.  
 Fecal hemoglobin levels were higher for patients with UC than in patients with 
CD at baseline. The mean fecal hemoglobin levels for patients with CD were consistently 
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low from baseline to infusion 1. However, fecal hemoglobin levels were elevated for 
patients with UC at baseline, infusion 1, and infusion 4. One patient with CD (previously 
mentioned) had high levels of fecal hemoglobin at baseline, along with high levels of 
fecal calprotectin and fecal lactoferrin. One patient with UC had the highest hemoglobin 
level from all three diagnostic groups at infusion 1. This patient also had high levels of 
fecal calprotectin and lactoferrin. This suggests that many of the biomarkers in this study 
follow the same pattern and can be used simultaneously to indicate the presence of 
inflammation. There was no significant difference in fecal hemoglobin levels between 
CD and those with UC from baseline to infusion 5.  
 There was no overall increase or decrease in IL1-a or IL1-b levels in patients 
with CD and those with UC from baseline to infusion 5. However, patients with UC had a 
spike increase in both IL1-a and IL1-b levels at infusion 4, and patients with CD had a 
spike increase in IL1-b levels at infusion 3. One patient with UC had the highest IL1-b 
level out of all the diagnostic groups at infusion 4. According to clinical notes, this 
patient presented with an upset stomach, loose stools, and vomiting - all of which are 
common GI symptoms of IBD. The number of patients with CD and UC identified as 
having high IL1-a or IL1-b levels were similar and spread out through the infusions. 
Additionally, patients with UC had higher IL1-a and IL1-b levels for a majority 
of the infusions. At baseline, patients with CD and UC had similar mean IL1-a values. 
However, patients with UC had a substantially greater mean IL1-b level than patients 
with CD at baseline. The trend in IL1-b levels for patients with UC from baseline to 
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infusion 5 paralleled that of other biomarkers, suggesting that IL1-b levels are promising 
in indicating the presence of inflammation for patients with UC.  
 Patients with CD had a significantly greater mean ESR levels than patients with 
UC at infusion 1 and a significantly greater mean CRP level than patients with UC at 
baseline and infusion 1. ESR and CRP are inflammatory biomarkers that are non-specific 
to IBD and cannot be used independently to indicate one’s IBD progression. However, it 
can be observed from the data that there is an increase in ESR and CRP levels at baseline 
and infusion 1 for patients with CD, indicating inflammation during this time. This was 
also the case for serum and fecal ASCA levels. This suggests that serum and fecal ASCA 
is a promising diagnostic tool in predicting inflammatory flares. This also suggests that 
patients with CD are more likely to have greater disease activity than patients with UC, at 
least at baseline and infusion 1.  
 The IMPACT-III questionnaire was used to measure a patient’s quality of life at 
the time of their appointment. There was no distinct positive or negative trend in total 
IMPACT-III scores for patients with UC. Patients with CD had a lower total score than 
patients with UC at baseline but had a higher total score than patients with UC by 
infusion 5. Patients with CD had a 9.2 point increase in IMPACT scores from baseline to 
infusion 5, whereas patients with UC had a 5.2 point increase. This means that patients 
with CD had a greater increase in total score from baseline to infusion 5 than patients 
with UC. However, both CD and UC groups showed an increase in their total IMPACT 
score. This suggests that the combination of clinical treatment and social support has a 
positive effect on the overall quality of life for IBD patients.  
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 As previously mentioned, the study is longitudinal and is still actively recruiting 
patients and collecting serum and fecal samples. The goal of this study is to recruit 50 
IBD patients: 30 Patients with CD, 15 patients with UC, and 5 patients with IC. 
Currently, we need 3 patients with CD in the induction phase of Remicade therapy and 4 
IC patients in any stage of Remicade therapy.  
It is important to note that the number of patients recruited doesn’t always match 
the number of serum and fecal samples collected. Many patients forget to bring stool 
samples to their appointments, even with reminders. Since the nurses collect serum 
samples in an outpatient setting, it is more likely that there will be more serum samples 
collected than stool samples. Additionally, there are many times when patients either 
cancel or reschedule their appointment without notice and so serum samples, stool 
samples, and IMPACT-III forms are not collected. To solve these problems, we have 
implemented weekly stool sample reminders to patients one week before their next 
Remicade appointment and weekly e-mails to both Longwood and Waltham CAT/CR 
centers, highlighting the active participants coming in for Remicade infusion appointment 
that week. We hope these measures will increase the number of stool samples collected 
and reduce the number of appointments missed.  
 We hope that with the completion of patient recruitment and sample collection, 
we will be able to determine better the role of inflammatory biomarkers such as ASCA, 
calprotectin, and lactoferrin in IBD disease activity in CD, UC, and IC pediatric patients. 
Overall, our data support the use of inflammatory biomarkers in evaluating the 
effectiveness of Remicade therapy in IBD and predicting inflammatory events. However, 
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